APA (7th ed.) Citation

Strober, B., Bachelez, H., Crowley, J., Elewski, B. E., Gooderham, M., Menter, A., . . . Armstrong, A. (2024). Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). Journal of the European Academy of Dermatology & Venereology, 38(5), 864. https://doi.org/10.1111/jdv.19748

Chicago Style (17th ed.) Citation

Strober, Bruce, et al. "Efficacy of Long‐term Risankizumab Treatment for Moderate‐to‐severe Plaque Psoriasis: Subgroup Analyses by Baseline Characteristics and Psoriatic Disease Manifestations Through 256 weeks (LIMMitless Trial)." Journal of the European Academy of Dermatology & Venereology 38, no. 5 (2024): 864. https://doi.org/10.1111/jdv.19748.

MLA (9th ed.) Citation

Strober, Bruce, et al. "Efficacy of Long‐term Risankizumab Treatment for Moderate‐to‐severe Plaque Psoriasis: Subgroup Analyses by Baseline Characteristics and Psoriatic Disease Manifestations Through 256 weeks (LIMMitless Trial)." Journal of the European Academy of Dermatology & Venereology, vol. 38, no. 5, 2024, p. 864, https://doi.org/10.1111/jdv.19748.